94 related articles for article (PubMed ID: 10052335)
1. Amgen's NESP victory cuts out Johnson & Johnson.
Fürst I
Nat Biotechnol; 1999 Feb; 17(2):124. PubMed ID: 10052335
[No Abstract] [Full Text] [Related]
2. Amgen's big-ticket play for Immunex.
Fletcher L
Nat Biotechnol; 2002 Feb; 20(2):105-6. PubMed ID: 11821840
[No Abstract] [Full Text] [Related]
3. Amgen's Japan deal.
Ratner M
Nat Biotechnol; 2008 Apr; 26(4):366. PubMed ID: 18392006
[No Abstract] [Full Text] [Related]
4. Can 'double blockbuster' strengthen Amgen's backbone?
Sheridan C
Nat Biotechnol; 2008 Apr; 26(4):361-3. PubMed ID: 18391999
[No Abstract] [Full Text] [Related]
5. Amgen's TPO mimic faces stiff competition.
Lawrence S
Nat Biotechnol; 2006 Sep; 24(9):1044. PubMed ID: 16964197
[No Abstract] [Full Text] [Related]
6. A generic problem.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
[No Abstract] [Full Text] [Related]
7. Striking the right balance between innovation and drug price competition: putting the Hatch-Waxman Act into perspective.
Deal JB
Food Drug Law J; 1999; 54(2):185-6. PubMed ID: 11759712
[No Abstract] [Full Text] [Related]
8. Can price and regulatory controls replace free market competition in the drug industry?
Buc NL; Levitt GM
Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
[No Abstract] [Full Text] [Related]
9. Competition and antitrust enforcement in the changing pharmaceutical marketplace.
Whitener MD
Food Drug Law J; 1995; 50(2):301-7. PubMed ID: 10342998
[No Abstract] [Full Text] [Related]
10. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
Rea TS
Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713
[No Abstract] [Full Text] [Related]
11. Effect of drug industry marketing practices on formularies questioned by federal agencies.
Gatty B
Hosp Formul; 1994 Nov; 29(11):786, 785. PubMed ID: 10138576
[No Abstract] [Full Text] [Related]
12. Drugmakers' price plan ruled to be price-fixing by agency.
Burda D
Mod Healthc; 1993 Oct; 23(41):8. PubMed ID: 10129330
[No Abstract] [Full Text] [Related]
13. Hoechst plans divestitures to gain FTC nod.
Scott L
Mod Healthc; 1995 Sep; 25(39):32. PubMed ID: 10151416
[No Abstract] [Full Text] [Related]
14. Correcting Hatch-Waxman.
Fernandes M
Health Aff (Millwood); 2008; 27(3):902-3; author reply 903. PubMed ID: 18475000
[No Abstract] [Full Text] [Related]
15. Generics battle brand names over mortality of drug patents.
Betz R
J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
[No Abstract] [Full Text] [Related]
16. The Hatch-Waxman Act: balancing competing interests or survival of the fittest?
Behrendt KE
Food Drug Law J; 2002; 57(2):247-71. PubMed ID: 12436990
[No Abstract] [Full Text] [Related]
17. Lilly deal's timing drew FTC notice.
Scott L
Mod Healthc; 1994 Oct; 24(43):8. PubMed ID: 10138136
[No Abstract] [Full Text] [Related]
18. Amgen asks judge for speedy ruling in patent case.
Nephrol News Issues; 1999 Dec; 13(12):14. PubMed ID: 11984928
[No Abstract] [Full Text] [Related]
19. Roger Perlmutter on shaping Amgen's R&D strategy. Interview by Christopher Watson.
Perlmutter RM
Drug Discov Today; 2005 Jun; 10(11):745-8. PubMed ID: 15922930
[No Abstract] [Full Text] [Related]
20. Who's really raising drug prices?
Zagorin A
Time; 1999 Mar; 153(9):46-8. PubMed ID: 10346086
[No Abstract] [Full Text] [Related]
[Next] [New Search]
